When Roche rumbles
The "Street" shakes. Mid-day April 21 announcement by Roche in Basel of a press conference on Monday, April 24 to "announce measures which are of considerable significance" sent analysts scurrying in search of march-in targets. Syntex has been a favorite rumor; but Roche announcement was apologetically rushed ("we beg for your understanding about the short term of this announcement"), and there isn't any ostensible reason for rushing a move on the California company. The window for breaking up the SmithKline-Beecham deal is more limited.
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.